RNTX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
6.1M
+16.2%
5.2M
-84.0%
32.7M
+494.7%
5.5M
-20.1%
6.9M
R&D
3.6M
+18.4%
3.1M
+53.6%
2.0M
+19.0%
1.7M
-60.8%
4.3M
SG&A
2.4M
+13.0%
2.2M
+10.2%
2.0M
-48.6%
3.8M
+47.8%
2.6M
Operating Income
-6076000
-16.2%
-5230000
+84.0%
-32659000
-494.7%
-5492000
+20.1%
-6871000
EBITDA
-6076000
-16.2%
-5230000
-32.1%
-3959000
+27.9%
-5492000
+20.1%
-6870000
Net Income
-6375000
-9.2%
-5838000
+81.7%
-31967000
-472.8%
-5581000
+18.2%
-6822000
EPS (Basic)
$-0.10
+47.4%
$-0.19
+82.6%
$-1.09
-419.0%
$-0.21
+25.0%
$-0.28
EPS (Diluted)
$-0.10
+47.4%
$-0.19
+82.6%
$-1.09
-419.0%
$-0.21
+25.0%
$-0.28
Shares (Diluted)
67.1M
+121.0%
30.4M
+3.5%
29.3M
+11.2%
26.4M
+9.0%
24.2M
Rein Therapeutics (RNTX) โ€” Financials